China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
2.100
+0.060 (2.94%)
Mar 6, 2026, 4:00 PM EST - Market closed
China SXT Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Revenue | 1.54 | 1.74 | 1.93 | 1.97 | 2.6 | 4.78 | |
| Revenue Growth (YoY) | -15.42% | -9.73% | -2.19% | -24.23% | -45.53% | -7.45% | |
| Cost of Revenue | 1.2 | 1.37 | 1.37 | 1.55 | 1.35 | 1.94 | |
| Gross Profit | 0.33 | 0.37 | 0.55 | 0.43 | 1.25 | 2.84 | |
| Selling, General & Admin | 8.72 | 3.05 | 2.65 | 5.68 | 6.44 | 5.04 | |
| Operating Expenses | 8.72 | 3.05 | 2.65 | 5.68 | 6.44 | 5.04 | |
| Operating Income | -8.38 | -2.68 | -2.09 | -5.26 | -5.19 | -2.2 | |
| Interest Expense | -0.68 | -0.84 | -0.55 | -0.48 | -0.04 | -1.12 | |
| Interest & Investment Income | 0.19 | 0.19 | 0.01 | - | 0 | 0.01 | |
| Other Non Operating Income (Expenses) | 0.01 | 0.03 | -0.04 | 0.15 | -0.18 | 0.36 | |
| EBT Excluding Unusual Items | -8.87 | -3.3 | -2.68 | -5.59 | -5.41 | -2.94 | |
| Asset Writedown | - | - | -0.42 | -0.35 | - | - | |
| Pretax Income | -8.87 | -3.3 | -3.1 | -5.93 | -5.41 | -2.94 | |
| Income Tax Expense | - | - | - | - | 0.33 | -0.19 | |
| Net Income | -8.87 | -3.3 | -3.1 | -5.93 | -5.74 | -2.75 | |
| Net Income to Common | -8.87 | -3.3 | -3.1 | -5.93 | -5.74 | -2.75 | |
| Free Cash Flow | -2.74 | -2.35 | -1.94 | -0.15 | 0.21 | -1.41 | |
| Gross Margin | 21.74% | 21.11% | 28.73% | 21.62% | 48.10% | 59.44% | |
| Operating Margin | -544.94% | -153.97% | -108.49% | -266.68% | -199.43% | -45.99% | |
| Profit Margin | -576.72% | -189.77% | -160.67% | -301.00% | -220.43% | -57.52% | |
| Free Cash Flow Margin | -178.33% | -134.83% | -100.34% | -7.68% | 7.91% | -29.50% | |
| EBITDA | -8.34 | -2.6 | -1.89 | -5.01 | -4.87 | -1.85 | |
| EBITDA Margin | - | -149.24% | -97.95% | -253.99% | -187.13% | -38.76% | |
| D&A For EBITDA | 0.05 | 0.08 | 0.2 | 0.25 | 0.32 | 0.35 | |
| EBIT | -8.38 | -2.68 | -2.09 | -5.26 | -5.19 | -2.2 | |
| EBIT Margin | - | -153.97% | -108.49% | -266.68% | -199.43% | -45.99% | |
| Revenue as Reported | 1.54 | 1.74 | 1.93 | 1.97 | 2.6 | 4.78 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.